Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

APRI 1.10 +0.01 (0.92%)
price chart
Apricus Biosciences, Inc Short Interest Update
Apricus Biosciences, Inc (NASDAQ:APRI), According to the latest information the short interest in Apricus Biosciences, Inc plummeted by 1.7% or 50,255 shares. The final shorts are 6.7% of the total floated shares. The positions dropped from 3,013,623 ...
Company Shares of Apricus Biosciences, Inc (NASDAQ:APRI) Drops by -10.4%
Apricus Biosciences, Inc (NASDAQ:APRI) has lost 10.4% during the past week and dropped 19.42% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 13.24%.
You Should Watch These: Advanced Micro Devices (NASDAQ:AMD), API ...  Property Mentor
Momentum Stock in Focus - Apricus Biosciences, Inc (NASDAQ:APRI)
According to Zacks, Apricus Biosciences, Inc (NASDAQ:APRI) has been given a high momentum style score. The score calculation is based on a number of factors indicating that the stock might be at a favorable level to enter a position based on the recent ...
Apricus Biosciences, Inc. : Apricus Biosciences to Present at the Stifel 2015 ...
SAN DIEGO, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will ...
Apricus Biosciences, Inc (NASDAQ:APRI) Price Target Update
Apricus Biosciences, Inc (NASDAQ:APRI) shares are expected to touch $4.63 in the short term. This short term price target has been shared by 4 analysts.
Apricus Biosciences: Be On The Look Out For Dilution
Apricus Biosciences had $7.4M in cash at the end of 2Q15 with an average burn of $5.5M per quarter. The company already announced it had drawn a final $5M from a credit facility during 3Q15, and believes it has sufficient cash to fund through 3Q16.
Taglich Brothers Initiates Coverage on Apricus Biosciences, Inc.
Apricus Biosciences, Inc., ( NASDAQ : APRI ) headquartered in San Diego, California, manufactures a treatment for erectile dysfunction and is developing pharmaceuticals to treat urological and rheumatoid disorders, and women's sexual disorders.
Top Growth Pick: Apricus Biosciences, Inc (NASDAQ:APRI)
Apricus Biosciences, Inc (NASDAQ:APRI) has received a top Growth Style score from Zack's Research. The growth score is based on company financials as well as the company's prospects for future growth.
Analysts' Recent Ratings Changes for Apricus Biosciences (APRI)
Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT?
Apricus Biosciences (ARPI) Stock Climbs Following Allergan License Agreement
"We rate APRICUS BIOSCIENCES INC (APRI) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most ...
3 Super Crazy Volume Spikes: Apricus Biosciences Inc (NASDAQ:APRI) Bristow ...  Wall Street Point
Apricus Biosciences Enters Into License Agreement With Allergan for the U.S ...  GlobeNewswire (press release)